Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetes type2 Clear all
Completed Not applicable Interventional

Acceptance and Commitment Therapy Principles for Diabetes Prevention

NCT05260983
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2, Diabetes, Diabetes type2
Interventions
Diabetes Prevention Education and Acceptance and Commitment Therapy, Diabetes Prevention Education Only
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

NCT00104182
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin NPH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

NCT01715818
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes Mellitus Type 2
Interventions
Placebo, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
1,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
143
States / cities
Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 17, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

Use of CGM in Kidney Transplant Recipients

NCT04783441
View directory record Official record
Conditions
Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Interventions
Dexcom G6, Dexcom G6 blinded sensor
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 17, 2026, 11:46 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Diabetes Nutrition Education for American Indian and Alaska Native Communities

NCT04254653
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
American Indian and Alaska Native What Can I Eat?
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Lakeport, California • Cherokee, North Carolina • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Not applicable Interventional

REACH-OUT: Chicago Children's Diabetes Prevention Program

NCT00723853
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Reach-Out Program, nutritional and exercise program, Reach-In Program, standard of care
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
9 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.

NCT00251680
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Tucson, Arizona • Artesia, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01407003
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 4 Interventional

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

NCT00732524
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glipizide, Glipizide and Glargine
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study

NCT04424888
View directory record Official record
Conditions
Diabetes Type 2, Diabetes Mellitus
Interventions
WB-011, Placebo, Continuous Glucose Monitor
Other · Device
Lead sponsor
Pendulum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 17, 2026, 11:46 PM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

NCT00143247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exubera® (inhaled insulin)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
12
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

NCT00355849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Fresno, California • Pomona, California • West Palm Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

NCT06326047
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0519-0130, Placebo, Trizepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
55
States / cities
Chula Vista, California • Fresno, California • Inglewood, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes

NCT00409240
View directory record Official record
Conditions
Diabetes, Hypertension, Dyslipidemia
Interventions
MEDIC
Other
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 17, 2026, 11:46 PM EDT
Completed No phase listed Observational

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

NCT01153438
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Bariatric Surgery
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Acceptance Based Coping Skills for Diabetes Delivered By Promotores

NCT06445725
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Acceptance Based Coping (ABaCo)
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

Effect of LY333531 on Vascular and Neural Functions

NCT00482976
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Ruboxistaurin, Placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Morning Light Treatment to Improve Glucose Metabolism

NCT03188263
View directory record Official record
Conditions
PreDiabetes, Circadian Dysregulation
Interventions
Bright Light, Dim Light
Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes

NCT00691249
View directory record Official record
Conditions
Hyperglycemia
Interventions
Resistant Starch Type 4-Raw, Resistant Starch Type 4-Cooked, Shredded Wheat
Dietary Supplement
Lead sponsor
Kansas State University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2009 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

NCT02004678
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-1150b, Placebo
Drug · Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Mulberry Leaf on Type 2 Diabetes

NCT00795704
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mulberry Leaf Extract, Placebo
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED

NCT06899191
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Hyperglycemia, Insulin Dependent Diabetes
Interventions
Hemoglobin A1c, Observation Unit
Diagnostic Test · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 17, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 17, 2026, 11:46 PM EDT